title: [Pfizer: TLV decision about antilipemic agents is founded on wrong basis].
authors.forename: Johan
authors.initials: J
authors.lastname: Brun
authors.forename: Ake
authors.initials: A
authors.lastname: Ohlsson-Onerud
authors.forename: Nikolaj
authors.initials: N
authors.lastname: Sörensen
mesh_terms: D000924:Anticholesteremic Agents / Q000008:administration & dosage / Q000191:economics; D000069059:Atorvastatin; D016265:Conflict of Interest; D016527:Drug Costs; D004345:Drug Industry / Q000191:economics; D016568:Drugs, Generic / Q000191:economics; D006538:Heptanoic Acids / Q000008:administration & dosage / Q000191:economics; D006801:Humans; D019161:Hydroxymethylglutaryl-CoA Reductase Inhibitors / Q000008:administration & dosage / Q000191:economics; D007356:Insurance, Pharmaceutical Services; D011758:Pyrroles / Q000008:administration & dosage / Q000191:economics; D019821:Simvastatin / Q000008:administration & dosage / Q000191:economics; D013548:Sweden
chemical_list: D000924:Anticholesteremic Agents; D016568:Drugs, Generic; D006538:Heptanoic Acids; D019161:Hydroxymethylglutaryl-CoA Reductase Inhibitors; D011758:Pyrroles; D000069059:Atorvastatin; D019821:Simvastatin